Aliases & Classifications for End Stage Renal Failure

MalaCards integrated aliases for End Stage Renal Failure:

Name: End Stage Renal Failure 12 15
End Stage Renal Disease 12 15
Chronic Kidney Disease Stage 5 71
Kidney Failure, Chronic 71


External Ids:

Disease Ontology 12 DOID:783
ICD10 32 N18.5
UMLS 71 C0022661 C2316810

Summaries for End Stage Renal Failure

MalaCards based summary : End Stage Renal Failure, also known as end stage renal disease, is related to frasier syndrome and nephrotic syndrome, type 1, and has symptoms including cloudy (hemodialysis) (peritoneal) dialysis effluent An important gene associated with End Stage Renal Failure is PKD1 (Polycystin 1, Transient Receptor Potential Channel Interacting), and among its related pathways/superpathways are Development Angiotensin activation of ERK and Pathways in cancer. The drugs tannic acid and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and bone, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 74 Chronic kidney disease (CKD) is a type of kidney disease in which there is gradual loss of kidney... more...

Related Diseases for End Stage Renal Failure

Diseases related to End Stage Renal Failure via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1298)
# Related Disease Score Top Affiliating Genes
1 frasier syndrome 33.7 WT1 PLCE1 NPHS2 NPHS1
2 nephrotic syndrome, type 1 33.6 WT1 NPHS2 NPHS1
3 nephrotic syndrome, type 2 33.5 PLCE1 NPHS2 NPHS1
4 alport syndrome 33.5 PKD1 MYH9 COL4A5 ALB
5 genetic steroid-resistant nephrotic syndrome 33.2 WT1 PLCE1 NPHS2 NPHS1
6 pierson syndrome 33.0 WT1 PLCE1 NPHS2 NPHS1 COL4A5
7 microvascular complications of diabetes 3 32.0 NPHS1 ALB AGTR1 ACE
8 peritonitis 31.8 TNF IL6 CRP ALB
9 secondary hyperparathyroidism 31.7 PTH EPO ALB
10 peripheral vascular disease 31.7 IL6 EPO CRP ALB ACE
11 limb ischemia 31.7 TNF IL6 ACE
12 glomerulonephritis 31.7 NPHS2 NPHS1 MYH9 FN1 COL4A5 ALB
13 acute kidney failure 31.6 UMOD CST3 ALB
14 amyloidosis 31.6 TNF IL6 CST3 CRP ALB
15 nutritional deficiency disease 31.6 IL6 EPO CRP ALB
16 uremia 31.6 TNF PTH IL6 EPO CRP ALB
17 pyelonephritis 31.6 UMOD TNF IL6 CRP ALB ACE
18 iga glomerulonephritis 31.6 NPHS2 NPHS1 ALB AGTR1 ACE
19 nephrotic syndrome 31.5 WT1 PLCE1 NPHS2 NPHS1 ALB ACE
20 viral hepatitis 31.5 TNF IL6 CRP ALB
21 malignant hypertension 31.5 AGTR1 AGT ACE
22 chronic pyelonephritis 31.5 UMOD ALB ACE
23 acute pancreatitis 31.5 TNF IL6 CRP ALB
24 acute myocardial infarction 31.5 IL6 FN1 CST3 CRP AGTR1 ACE
25 intermediate coronary syndrome 31.4 IL6 CRP ALB ACE
26 peripheral artery disease 31.4 TNF IL6 CST3 CRP ACE
27 calciphylaxis 31.4 PTH FN1 EPO ALB
28 lipoid nephrosis 31.4 WT1 NPHS2 NPHS1 ALB
29 cardiac tamponade 31.4 CRP ALB ACE
30 interstitial nephritis 31.4 UMOD CRP ALB AGTR1 AGT ACE
31 polycystic kidney disease 31.4 PKD1 EPO CST3 ALB AGTR1 AGT
32 vascular disease 31.4 TNF PTH IL6 FN1 EPO CST3
33 uremic pruritus 31.3 IL6 CRP
34 kidney disease 31.3 WT1 UMOD TNF PTH PKD1 NPHS2
35 renovascular hypertension 31.3 PKD1 AGTR1 ACE
36 angina pectoris 31.3 IL6 CRP ACE
37 glomerular disease 31.3 NPHS2 NPHS1 COL4A5 ALB ACE
38 fabry disease 31.3 UMOD TNF IL6 CST3 CRP
39 hyperphosphatemia 31.3 PTH CRP ALB
40 purpura 31.3 TNF IL6 CRP ACE
41 nephrosclerosis 31.3 TNF NPHS2 NPHS1 AGTR1 ACE
42 microvascular complications of diabetes 5 31.3 ALB AGTR1 AGT ACE
43 arteriosclerosis 31.3 IL6 CST3 CRP ACE
44 aortic aneurysm, familial abdominal, 1 31.3 IL6 CST3 CRP ACE
45 denys-drash syndrome 31.3 WT1 PLCE1 NPHS2 NPHS1
46 cystitis 31.3 UMOD TNF IL6 CST3 CRP
47 myeloma, multiple 31.3 TNF PTH IL6 FN1 EPO CRP
48 obstructive nephropathy 31.3 ALB AGT ACE
49 cardiogenic shock 31.2 IL6 CRP
50 appendicitis 31.2 TNF IL6 CRP ALB

Graphical network of the top 20 diseases related to End Stage Renal Failure:

Diseases related to End Stage Renal Failure

Symptoms & Phenotypes for End Stage Renal Failure

UMLS symptoms related to End Stage Renal Failure:

cloudy (hemodialysis) (peritoneal) dialysis effluent

MGI Mouse Phenotypes related to End Stage Renal Failure:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.45 ACE AGT AGTR1 ALB COL4A5 CRP
2 homeostasis/metabolism MP:0005376 10.38 ACE AGT AGTR1 ALB COL4A5 CRP
3 growth/size/body region MP:0005378 10.27 ACE AGT AGTR1 FN1 GATA3 IL6
4 immune system MP:0005387 10.27 ACE AGT AGTR1 ALB COL4A5 CRP
5 hematopoietic system MP:0005397 10.21 ACE AGTR1 COL4A5 EPO FN1 GATA3
6 mortality/aging MP:0010768 10.19 ACE AGT AGTR1 ALB COL4A5 CST3
7 adipose tissue MP:0005375 10.15 ACE AGT AGTR1 COL4A5 GATA3 IL6
8 liver/biliary system MP:0005370 9.97 ACE AGT ALB EPO FN1 IL6
9 muscle MP:0005369 9.9 AGT ALB CST3 EPO FN1 GATA3
10 neoplasm MP:0002006 9.61 ACE ALB CST3 FN1 IL6 PKD1
11 renal/urinary system MP:0005367 9.44 ACE AGT AGTR1 ALB COL4A5 GATA3

Drugs & Therapeutics for End Stage Renal Failure

Drugs for End Stage Renal Failure (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 690)
# Name Status Phase Clinical Trials Cas Number PubChem Id
tannic acid Approved Phase 4 1401-55-4
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
Capsaicin Approved Phase 4 404-86-4 1548943
Simvastatin Approved Phase 4 79902-63-9 54454
Eplerenone Approved Phase 4 107724-20-9 150310 443872
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
Digoxin Approved Phase 4 20830-75-5 30322 2724385
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
Alendronate Approved Phase 4 66376-36-1, 121268-17-5 2088
Ezetimibe Approved Phase 4 163222-33-1 150311
Hydroxychloroquine Approved Phase 4 118-42-3 3652
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
Nadroparin Approved, Investigational Phase 4
Methyldopa Approved Phase 4 555-30-6 38853
Glimepiride Approved Phase 4 93479-97-1 3476
Ticlopidine Approved Phase 4 55142-85-3 5472
Telavancin Approved Phase 4 372151-71-8
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
Argatroban Approved, Investigational Phase 4 74863-84-6 152951
Dolutegravir Approved Phase 4 1051375-16-6 54726191
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
Liraglutide Approved Phase 4 204656-20-2 44147092
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198
Ramipril Approved Phase 4 87333-19-5 5362129
leucovorin Approved Phase 4 58-05-9 6006 143
Ribavirin Approved Phase 4 36791-04-5 37542
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
Donepezil Approved Phase 4 120014-06-4 3152
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
Pantoprazole Approved Phase 4 102625-70-7 4679
Insulin aspart Approved Phase 4 116094-23-6 16132418
39 Taurolidine Approved, Investigational Phase 4 19388-87-5
Enoxaparin Approved Phase 4 9005-49-6 772
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
Remifentanil Approved Phase 4 132875-61-7 60815
Desflurane Approved Phase 4 57041-67-5 42113
Thiopental Approved, Vet_approved Phase 4 76-75-5 3000715
Bacitracin Approved, Vet_approved Phase 4 1405-87-4 439542 10909430
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
Deflazacort Approved, Investigational Phase 4 14484-47-0
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
Colchicine Approved Phase 4 64-86-8 6167 2833
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 158781 130881

Interventional clinical trials:

(show top 50) (show all 2362)
# Name Status NCT ID Phase Drugs
1 A Prospective Randomized, Double-Blind Parallel Group Trial To Assess The Efficacy And Safety Of Intravenous Dextrose 5% Solution Compare With Normal Saline (Standard Care) In Rinsing During Haemodialysis In Subjects With End Stage Renal Failure (ESRF) With Respect To Systolic Blood Pressure Control Over 3 Months Period. Unknown status NCT02590081 Phase 4 Dextrose 5%;normal saline
2 Effects of On-Line Hemodiafiltration(HDF) on Endothelial Dysfunction in Chronic Hemodialysis Patients Unknown status NCT00532597 Phase 4
3 Simvastatin Effect on Endothelium Dependent Venodilation in Chronic Renal Failure Patients Treated by Peritoneal Dialysis Unknown status NCT00291863 Phase 4 Simvastatin
4 The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Critical Ischaemia in Patients With End-stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
5 Inspiratory Muscle Training in Patients With End Stage Renal Failure: a Randomized Controlled Trial Unknown status NCT01347775 Phase 4
6 The Association Between Body Composition and Biomarkers in Hemodialysis Patients Unknown status NCT01103167 Phase 4
7 The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients Unknown status NCT00247507 Phase 4 acetylcysteine
8 A comParison on Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Study Among SeVerE Chronic Kidney Disease/ End-Stage-Renal-Disease Patients With Recent Acute Coronary Syndrome. Unknown status NCT02459288 Phase 4 Clopidogrel first;Ticagrelor first
9 Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease Unknown status NCT00852787 Phase 4 Digoxin immune fab;Placebo
10 A Pilot Study to Treat Patients With Chronic HCV Genotype 1 and ESRD Receiving Hemodialysis and Naïve to Prior HCV Therapy With Peginterferon Alfa-2b, the Maximally Tolerated Ribavirin Dose and Boceprevir Unknown status NCT01731301 Phase 4 Ribavirin;Peginterferon;Boceprevir
11 The Effect of Ferric Citrate on Inflammation and Lipid Levels in Patients on Hemodialysis Unknown status NCT02661295 Phase 4 Ferric Citrate
12 Calcineurin Inhibitor Minimisation in Renal Transplant Recipients With Stable Allograft Function: A Prospective Randomised Controlled Trial Unknown status NCT00541814 Phase 4 Cyclosporine
13 A Phase-IV Study Comparing Standard Release Tacrolimus (Prograf) vs Prolonged-release Tacrolimus (Advagraf) Monotherapy as Maintenance Immunosuppression After Induction With Alemtuzumab in Kidney Transplantation Unknown status NCT00807144 Phase 4 Tacrolimus (Kidney transplant maintenance immunosuppression);Kidney transplant maintenance immunosuppression
14 The Effect of Far Infrared (FIR) Therapy on Access Flow of Arteriovenous (AV) Fistula, Echocardiographic Parameters and Endothelial Function in Patients With End Stage Renal Disease Unknown status NCT01138254 Phase 4
15 Comparison of Onset of Action Between 2% Lidocaine Plus 0.5% Bupivacaine and 0.5% Bupivacaine in Brachial Plexus Anesthesia for Creation of Arteriovenous Fistula in ESRD Patient Unknown status NCT00993746 Phase 4 Bupivacaine plus lidocaine;Bupivacaine 30 ml
16 A Comparative Study of Dexmedetomidine and Propofol As Sole Sedative Agent for Patients With End-Stage Renal Disease Undergoing Arteriovenous Fistula Surgery Unknown status NCT02447796 Phase 4 Propofol;Dexmedetomidine
17 Hemocontrol's Effectiveness in a RAndomized Controlled Trial on the Reduction of Cardiovascular Long-term EventS Unknown status NCT01515878 Phase 4
18 The Impact of Conventional Hemodialysis, High Flux Hemodialysis and Hemodiafiltration on Adiponectin, Vascular Function and Clinical Prognosis Unknown status NCT00155363 Phase 4
19 The Determinants of the Effectiveness of the Use of Furosemide in Patients on Dialysis Unknown status NCT01815892 Phase 4 Withdrawal of furosemide;furosemide administration
20 Renoprotection by Combining Pentoxifylline and Angiotensin Blockade in Chronic Kidney Disease Unknown status NCT01377285 Phase 4 ARB;Pentoxifylline;Placebo (for Pentoxifylline)
21 The Efficacy and Safety of Niacin on Hyperphosphatemia in End Stage Renal Disease Patients Undergoing Haemodialysis Unknown status NCT03163576 Phase 4 Niacin;Phosphate Binder
22 Clinical Trial, Open, Parallel Groups , Value the Antiproteinuric Effects From Vitamin D Derivatives in Patient With Chronic Kidney Illness and the Lack of Vitamin D Unknown status NCT01442272 Phase 4 Hidroferol®;Paricalcitol: Zemplar®;Habitual medication
23 Renal Toxicity of Iodixanol and Iopromide in Patients With Renal Dysfunction—a Multicentre, Single Blind, Randomized Controlled, Prospective Trial Unknown status NCT01580046 Phase 4 iodixanol;iopromide
24 Protective Mechanisms of Aldosterone Antagonists and Their Effects on Cardiovascular Damage in Chronic Renal Failure: Clinical and Experimental Studies Unknown status NCT00277693 Phase 4 Spironolactone (drug)
25 Effect of Hydration With Sodium Bicarbonate for Long-Term Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing an Emergent Coronary Procedure Unknown status NCT00716001 Phase 4 N-acetylcysteine
26 Upstream Use of Aliskiren in Hypertensive Haemodialysis Patients: Effects on Cardiovascular Outcomes Unknown status NCT01635387 Phase 4 aliskiren
27 Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease: An Interventional and Methodological Study Unknown status NCT00235287 Phase 4 Candesartan and enalapril;candesartan and enalapril;candesartan and enalapril;candesartan and enalapril
28 Open Randomized Phase IV Study on Intravenous Iron in Anemic Patients With Chronic Kidney Disease Unknown status NCT00204256 Phase 4 Iron sucrose
29 The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease Unknown status NCT01157260 Phase 4 Kremezin
30 The Metabolic and Anti-Inflammatory Effects of Combined Ezetimibe and Simvastin Therapy, as Compared to Simvastatin Alone, in Patients With Chronic Proteinuric Nephropathy Unknown status NCT00861731 Phase 4 simvastatin;EZE/simvastatin;EZE/simvastatin
31 NAC in Preventing CIN in CRF Patients Who Need Enhanced CT Scan in ED Unknown status NCT00501475 Phase 4 NAC Bicarbonate
32 Randomized, Open Label, Controlled Clinical Trial of Egg Albumin-Based Protein Supplement Versus Renal Specific Oral Supplement in Hemodialysis Patients Unknown status NCT01981083 Phase 4
33 Phase 4 Study of Medical Therapy Versus Medical Therapy Plus Renal Artery Stenting in Preventing the Progression of Renal Failure in Atherosclerotic Renovascular Disease Unknown status NCT01023373 Phase 4 Medical treatment
34 The Immunogenicity and Safety of the Seasonal Influenza Vaccine, Formulation 2013-2014, in Chronic Kidney Disease Patients Not on Dialysis Unknown status NCT02105519 Phase 4
35 A Randomized, Open, Controlled, Parallel Group Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin Therapy Unknown status NCT03320031 Phase 4 Linagliptin;Humalog Mix 75/25
36 Clinical Impact of Bacteriuria on Chronic Inflammation in Asymptomatic Hemodialysis Patients Unknown status NCT01570556 Phase 4
37 N-Acetylcysteine to Prevent Contrast-Induced Nephropathy in Acute Coronary Syndromes Unknown status NCT00939913 Phase 4 intravenous NAC;Placebo
38 Efficacy of Pregabalin in the Management of Chronic Uremic Pruritus Unknown status NCT01073501 Phase 4 Pregabalin;Placebo
39 The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
40 Lithium in Cardiac Surgery Related Acute Kidney Injury: A Pilot Study Unknown status NCT03056248 Phase 4 Placebo oral capsule;Lithium Carbonate
41 Interstitial Fibrosis in Protocol Biopsies of Renal Allografts: A Prospective, Randomised Trial of Sirolimus Versus Cyclosporine.(Fibrasic) Unknown status NCT00493194 Phase 4 sirolimus;cyclosporine;daclizumab
42 Effect of Short-term Synbiotic Treatment on Plasma P-cresol Levels in Hemodialysis Patients Unknown status NCT02311868 Phase 4
43 Phase 4 Study of Mechanisms of Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy Unknown status NCT01300273 Phase 4
44 Effect of Ursodeoxycholic Acid on Peritoneal Function in Patients on Peritoneal Dialysis Unknown status NCT02338635 Phase 4 Ursodeoxycholic Acid
45 Phase 4 Study of Alprostadil Prevent Contrast Induced Nephropathy in Patients Receiving a Cardiac Catheterization Unknown status NCT01722513 Phase 4 Alprostadil ﹠control
46 A Randomized Prospective Trial of N-acetyl Cystein in Patients With Peritoneal Dialysis Unknown status NCT01111422 Phase 4 N-acetylcysteine
47 Providing Intravenous Paricalcitol Treatment to the Sick and Poor Chronic Hemodialysis Patients With Severe Secondary Hyperparathyroidism Resistant to Existing Vitamin D Analogs Unknown status NCT03023748 Phase 4 Intravenous Paricalcitol
48 Hypervolemia and Treatment Guided by Bioimpedance in End Stage Renal Disease Patients in Zonguldak (Prospective Study) Unknown status NCT01468363 Phase 4
49 Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Unknown status NCT01673204 Phase 4 Calcitriol;Placebo
50 Peripheral Artery Disease in Patients on Maintenance Hemodialysis: Risk Factors and the Effect of FIR Therapy Unknown status NCT01095549 Phase 4

Search NIH Clinical Center for End Stage Renal Failure

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Aluminum carbonate
basic aluminum carbonate gel
calcium acetate
Calcium Carbonate
Calcium gluceptate
dihydroxyaluminum sodium carbonate
Ethacrynate Sodium
Ethacrynic Acid
Magnesium Hydroxide

Genetic Tests for End Stage Renal Failure

Anatomical Context for End Stage Renal Failure

MalaCards organs/tissues related to End Stage Renal Failure:

Kidney, Heart, Bone, Liver, Endothelial, Pancreas, Testes

Publications for End Stage Renal Failure

Articles related to End Stage Renal Failure:

(show top 50) (show all 35486)
# Title Authors PMID Year
Fluid resuscitation in patients with end-stage renal disease on hemodialysis presenting with severe sepsis or septic shock: A case control study. 61
31733623 2020
Tackling endothelium remodeling in cardiovascular disease. 61
31490028 2020
Diffuse dermal angiomatosis associated with calciphylaxis: A 5-year retrospective institutional review. 61
31589777 2020
Conservative vs. preservative management of chronic kidney disease: similarities and distinctions. 61
31743240 2020
Predictive Factors for Unsuccessful Use of Arteriovenous Fistula in a Population of End-Stage Renal Disease Patients in Southeastern Mexico. 61
31449952 2020
Incidence and Risk of Carpal Tunnel Syndrome in End-Stage Renal Disease Patients on Dialysis: A Nationwide Population-Based Matched Cohort Study. 61
31833895 2020
Can physicians detect hyperkalemia based on the electrocardiogram? 61
31047740 2020
Novel options for failing allograft in kidney transplanted patients to avoid or defer dialysis therapy. 61
31743241 2020
Bone mineral density at different sites and 5 years mortality in end-stage renal disease patients: A cohort study. 61
31669253 2020
Diabetic Nephropathy: An Overview. 61
31701441 2020
Methods to Detect Endoplasmic Reticulum Stress and Apoptosis in Diabetic Nephropathy. 61
31701452 2020
MicroRNA-544 attenuates diabetic renal injury via suppressing glomerulosclerosis and inflammation by targeting FASN. 61
31323309 2020
Applicability of laboratory deficit-based frailty index in predominantly older patients with end-stage renal disease under chronic dialysis: A pilot test of its correlation with survival and self-reported instruments. 61
30834584 2020
Case 277. 61
31846409 2020
Safety and Efficacy of Direct Oral Anticoagulants Versus Warfarin in Patients With Chronic Kidney Disease and Atrial Fibrillation. 61
31780073 2020
Tunneled hemodialysis catheter care practices and blood stream infection rate in children: results from the SCOPE collaborative. 61
31654224 2020
Noncontrast Magnetic Resonance Lymphangiography in a Rare Case of Everolimus-Related Lymphedema. 61
31663933 2020
Body composition changes assessment by bioelectrical impedance vectorial analysis in right heart failure and left heart failure. 61
31421949 2020
Intestinal dialysis for conservative management of Uremia. 61
31725008 2020
Perspiration interventions for conservative management of kidney disease and uremia. 61
31743242 2020
Impact of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on renal and mortality outcomes in people with Type 2 diabetes and proteinuria. 61
31407377 2020
Renal outcomes of neonates with early presentation of posterior urethral valves: a 10-year single center experience. 61
31471579 2020
Histological Examination of the Diabetic Kidney. 61
31701446 2020
Impact of Physical Function on 1-Year Kidney Transplant Outcomes. 61
30841792 2020
Impact of chronic kidney disease on in-hospital outcomes following left ventricular assist device placement: A national perspective. 61
31153604 2020
Factors influencing the timing of initiation of renal replacement therapy and choice of modality in children with end-stage kidney disease. 61
31654222 2020
Recovery of renal function in patients with lupus nephritis and reduced renal function: the beneficial effect of hydroxychloroquine. 61
31793379 2020
Circulating FGF23 is not associated with cardiac dysfunction, atherosclerosis, infection or inflammation in hemodialysis patients. 61
31420749 2020
Everyday life experiences in families with a child with kidney disease. 61
31453665 2019
Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design. 61
31571136 2019
Impacts of Sex Differences in Pulse Pressure among Patients with Chronic Kidney Disease. 61
31835400 2019
On the role of skin biopsy in the diagnosis of calcific uremic arteriolopathy: a case-based discussion. 61
31792896 2019
The gut microbiota and its relationship with chronic kidney disease. 61
31576489 2019
Association of thyroid status prior to transition to end-stage renal disease with early dialysis mortality. 61
30299498 2019
Efficacy of xanthine oxidase inhibitor for chronic kidney disease patients with hyperuricemia. 61
31845065 2019
Refractory CD20 Positive Cellular Rejection in Living Kidney Transplant: A Case Report and Review of Literature. 61
29534659 2019
Primary Hyperoxaluria-Imaging of Renal Oxalosis. 61
31585197 2019
Pulse Pressure and the Risk of End-Stage Renal Disease Among Chinese Adults in Singapore: The Singapore Chinese Health Study. 61
31766974 2019
Alteration autonomic control of cardiac function during hemodialysis predict cardiovascular outcomes in end stage renal disease patients. 61
31827106 2019
Periodontitis is associated with oral health-related quality of life in individuals with end-stage renal disease. 61
31834630 2019
Dietary Protein and Physical Activity Interventions to Support Muscle Maintenance in End-Stage Renal Disease Patients on Hemodialysis. 61
31817402 2019
Oxalate retinopathy is irreversible despite early combined liver-kidney transplantation in primary hyperoxaluria type 1. 61
31152479 2019
The impact of tonsillectomy combined with steroid pulse therapy in patients with advanced IgA nephropathy and impaired renal function. 61
31845064 2019
Matrix-assisted laser desorption/ionization mass spectrometry imaging to uncover protein alterations associated with the progression of IgA nephropathy. 61
31838587 2019
Maximum Glomerular Diameter and Oxford MEST-C Score in IgA Nephropathy: The Significance of Time-Series Changes in Pseudo-R2 Values in Relation to Renal Outcomes. 61
31810207 2019
Psychiatric Profile of Patients Currently Listed for Kidney Transplantation: Evidence of the Need for More Thorough Pretransplant Psychiatric Evaluations. 61
31732207 2019
An unusual case of peritoneal dialysis-associated bacterial peritonitis caused by Weeksella virosa. 61
31813264 2019
Paclitaxel-coated balloon in the treatment of recurrent dysfunctional arteriovenous access, real-world experience and longitudinal follow up. 61
30901497 2019
Hemiarthroplasty in the Hip Fracture Patient with Renal Impairment: To Cement or Not to Cement. 61
31824876 2019
Cumulative fluid accumulation is associated with the development of acute kidney injury and non-recovery of renal function: a retrospective analysis. 61
31796077 2019

Variations for End Stage Renal Failure

ClinVar genetic disease variations for End Stage Renal Failure:

6 ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PKD1 NM_001009944.3(PKD1):c.2079dup (p.Pro694fs)duplication Pathogenic 374141 rs1057518923 16:2165397-2165397 16:2115396-2115396
2 GATA3 NM_001002295.2(GATA3):c.1051-1G>CSNV Pathogenic 430696 rs112417755 10:8115701-8115701 10:8073738-8073738
3 COL4A4 NM_000092.4(COL4A4):c.4217-15T>CSNV Conflicting interpretations of pathogenicity 255039 rs200926310 2:227877028-227877028 2:227012312-227012312
4 COL4A4 NM_000092.4(COL4A4):c.3055G>C (p.Glu1019Gln)SNV Uncertain significance 374041 rs1057518854 2:227915788-227915788 2:227051072-227051072

Expression for End Stage Renal Failure

Search GEO for disease gene expression data for End Stage Renal Failure.

Pathways for End Stage Renal Failure

Pathways related to End Stage Renal Failure according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
Show member pathways
2 12.61 IL6 FN1 EPO COL4A5 AGTR1 AGT
Show member pathways
Show member pathways
5 11.85 TNF IL6 GATA3 AGT
6 11.68 TNF IL6 GATA3 FN1
Show member pathways
8 11.57 TNF IL6 FN1 COL4A5
9 11.54 AGTR1 AGT ACE
10 11.33 TNF IL6 FN1
12 11.29 TNF PTH IL6
13 11.17 TNF PLCE1 IL6 FN1 COL4A5 AGTR1
14 11.05 TNF IL6 GATA3
15 10.74 TNF IL6 FN1 CRP

GO Terms for End Stage Renal Failure

Cellular components related to End Stage Renal Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell GO:0005623 9.87 PTH PLCE1 PKD1 MYH9 IL6 AGTR1
2 extracellular exosome GO:0070062 9.85 UMOD PKD1 NPHS2 NPHS1 MYH9 FN1
3 extracellular region GO:0005576 9.73 UMOD TNF PTH IL6 FN1 EPO
4 endoplasmic reticulum lumen GO:0005788 9.65 IL6 FN1 CST3 COL4A5 ALB
5 slit diaphragm GO:0036057 9.37 NPHS2 NPHS1
6 extracellular space GO:0005615 9.36 TNF PTH IL6 FN1 EPO CST3

Biological processes related to End Stage Renal Failure according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 10.03 WT1 TNF IL6 GATA3 EPO AGT
2 cellular protein metabolic process GO:0044267 9.94 IL6 FN1 CST3 ALB
3 positive regulation of cytosolic calcium ion concentration GO:0007204 9.85 PLCE1 PKD1 AGTR1 AGT
4 positive regulation of gene expression GO:0010628 9.85 WT1 TNF IL6 GATA3 FN1 CRP
5 regulation of cell growth GO:0001558 9.82 PLCE1 AGTR1 AGT
6 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.81 TNF IL6 EPO
7 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.77 PLCE1 AGTR1 AGT
8 humoral immune response GO:0006959 9.75 TNF IL6 GATA3
9 negative regulation of fat cell differentiation GO:0045599 9.74 TNF IL6 GATA3
10 response to salt stress GO:0009651 9.65 TNF EPO
11 mesenchymal to epithelial transition GO:0060231 9.63 WT1 GATA3
12 excretion GO:0007588 9.63 UMOD NPHS2 NPHS1
13 glomerular basement membrane development GO:0032836 9.62 WT1 NPHS1
14 glomerulus development GO:0032835 9.62 WT1 PLCE1
15 positive regulation of cholesterol esterification GO:0010873 9.61 AGTR1 AGT
16 neutrophil mediated immunity GO:0002446 9.61 IL6 ACE
17 positive regulation of cytokine production GO:0001819 9.61 TNF GATA3 AGT
18 positive regulation of T-helper 2 cell cytokine production GO:2000553 9.59 IL6 GATA3
19 positive regulation of NAD(P)H oxidase activity GO:0033864 9.58 AGTR1 AGT
20 metanephric ascending thin limb development GO:0072218 9.54 UMOD PKD1
21 regulation of renal sodium excretion GO:0035813 9.52 AGTR1 AGT
22 calcium-independent cell-matrix adhesion GO:0007161 9.51 PKD1 FN1
23 regulation of vasoconstriction GO:0019229 9.5 AGTR1 AGT ACE
24 renin-angiotensin regulation of aldosterone production GO:0002018 9.49 AGTR1 AGT
25 regulation of blood vessel diameter by renin-angiotensin GO:0002034 9.48 AGTR1 AGT
26 acute-phase response GO:0006953 9.46 IL6 FN1 EPO CRP
27 negative regulation of lipid storage GO:0010888 9.43 TNF IL6 CRP
28 regulation of renal output by angiotensin GO:0002019 9.4 AGT ACE
29 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.13 AGTR1 AGT ACE
30 kidney development GO:0001822 9.1 WT1 PKD1 GATA3 AGTR1 AGT ACE

Molecular functions related to End Stage Renal Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 bradykinin receptor binding GO:0031711 8.62 AGTR1 ACE

Sources for End Stage Renal Failure

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....